Replies to post #321692 on Avid Bioservices Inc (CDMO)

[biopharm]

Looks like never, unless Lias allowing many to believe there is no movement behind the curtains and big contracts await for the IP give away

[biopharm]

How about everyone that is invested in Peregrine pharmaceuticals plays connect the dots

"Dr Bernhard Hampl with ties to Great Point Partners and Cambrex...the same Cambrex where Gregory Sargen was CEO with right hand man Dr Ron Carroll with BMS ties with Gerald Finken.... much more investigating should be done ..."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133039636

There are dozens of names to add...and we shall....but when this is complete one will be shocked to see the ties to CSM in Fargo ND

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133089427

___________

Private equity firm makes $2.4B offer to purchase CDMO Cambrex

8/8/2019

https://www.smartbrief.com/branded/D4C8EBAD-9C67-4D55-869C-CC2C8F893F9E/9953DBA8-C7B3-4B0D-9A3D-4042CD7D45A4

______

Gregory P. Sargen currently serves as Executive Vice President â?? Corporate Development and Strategy of Cambrex Corporation (NYSE:CBM) (â??Cambrexâ?), a global manufacturer and provider of services to life sciences companies. Prior to his current role, Mr. Sargen served as Executive Vice President and Chief Financial Officer of Cambrex. Prior to Cambrex, Mr. Sargen served as Vice President of Finance â?? Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Deloitte & Touche LLP. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.

https://avidbio.com/team-member/gregory-p-sargen/

__________

Thermo Fisher Scientific to Buy Brammer Bio for $1.7 Billion

Published: Mar 25, 2019

https://www.biospace.com/article/thermo-fisher-scientific-to-buy-brammer-bio-for-1.7 billion/

______

The road to riches continue for many involved with Peregrine, now Avid and looks like the CDMO sector is sizzling

What is Bamforth up to with placing on his LinkedIn profile "more to follow shortly .." ? and the puzzle continues to solidify....Hell, I bet the ticker symbol "CDMO" could be sold for big bucks and imagine that...it had to be reserved LONG ago for Avid Bioservices because wouldn't many other CDMOs want to have CDMO as their ticker, maybe Arranta Bio could be so lucky so how much space in Watertown could Avid pick up? I say pick up because Mark Bamforth certainly wouldn't live up to the fiduciary duties of the BOD to not expand Avid somehow, sooner than later ...because CDMOs are being bought for bigger bucks and Avid would command the biggest with the PS Targeting IP assets built into the revenue streams

_____


Arranta Bio LLC is a Massachusetts Foreign Limited-Liability Company (Llc) filed on May 16, 2019. The company's File Number is listed as 001384283.

The Registered Agent on file for this company is Cogency Global Inc and is located at 45 School Street, Ste 202, Boston, MA 02108. The company's principal address is 99 Irving Street, Cambridge, MA 02138.

The company has 1 principal on record. The principal is Mark Robert Bamforth from Cambridge MA.

______

ARRANTA BIO LLC BRANCH

Company Number
001384283
Incorporation Date
16 May 2019 (3 months ago)
Company Type
Foreign Limited Liability Company (LLC)
Jurisdiction
Massachusetts (US)
Branch
Branch of Delaware (US) company
Registered Address
99 IRVING STREET
CAMBRIDGE,
02138
MA
USA
Agent Name
COGENCY GLOBAL INC
Agent Address
45 SCHOOL STREET STE 202, BOSTON, MA, 02108, USA
Directors / Officers
COGENCY GLOBAL INC, agent
MARK ROBERT BAMFORTH, manager
MARK ROBERT BAMFORTH, real property

https://opencorporates.com/companies/us_ma/001384283

______

Mark Bamforth

Experience

President & CEO
Arranta Bio
August 2019 - Present 1 month
Watertown, MA
Arranta Bio is a contract development and manufacturing organization (CDMO).... more to follow shortly.

Board Member
Avid Bioservices
October 2017 - Present 1 year 11 months
Tustin, CA

_______

After Dr. Wolchok's finding and publication/presentations on the subject, PPHM PdtSer-Targeting is the perfect replacement for OX40 and alikes in CAR-T for all solid cancers. ex-CEO King said renewed interest and Dr/ Wolchok said a test on humans is designed and waits for the company (understand->'the green light') to start.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137369922

[Globewriter]

A special request message on business model of Avid Bioservices

CP, would you want to comment on current state of affairs ? ( of the battle for PS Targeting : )

Lots has taken place and biomarkers skipping out the door left and right it seems making fortunes for others ...and with a contract comes the duty to pursue betabodies / biomarkers yet no verification from no sides

REMEMBER

PS-Targeting plays on MANY fields. NCCN trials with Chemo and Radio will have NO resistance IMO. They will just bring more to the table on HOW PdtSer targeting combines with others and possibly allow to fine tune or confirm the MOA.

In the new field of Immuno Therapy and more specifically Immuno Oncology which includes the traditional phase I MONO Therapies anti-PD-1, anti-CTLA-4, CAR-T, etc PdtSer-targeting has no role to play. It is clearly a drug that you need to combine with something else.

In phase II COMBINATION therapies the war is on between BP's and the 200-300% increase you mention when PdtSer-Targeting is added is in that anti-PD-1 and anti-CTLA-4 arena. (Dr Brekken's results @ UTSW). We have a test, Yervoy (anti-CTLA-4) plus Bavituximab (19 patients of 22 treated then stopped because the SOC (Standard of Care) changed). Yet we NEVER saw those results and that is because either BMY or PPHM didn't want us to see them because it is UNTHINKABLE that they would not have processed and monitored the results of this open (not-blinded) trial.

But the above is under attack by CAR-T. As I wrote in an elaborate post on the question CAR-T is more comfort for the patient, a better technique with better results but in solid cancers sees all that be broken down to the ground because of the toxicity of immuno modulators such as OX40 that are needed in the process. CAR-T offers CURE vs anti-XYZ offer live prolongement only.

After Dr. Wolchok's finding and publication/presentations on the subject, PPHM PdtSer-Targeting is the perfect replacement for OX40 and alikes in CAR-T for all solid cancers. ex-CEO King said renewed interest and Dr/ Wolchok said a test on humans is designed and waits for the company (understand->'the green light') to start.

Novartis CEO said on CNBC that the biotechs that remain are expensive. Gilead CEO was looking for cornerstone molecules and with KITE stepped into CAR-T. And ROCHE is the other deep pocket player in the field. All will want to grow BEHIND the current limitations to non-solid cancers. The market for solid cancers is BIG, HUGE and will engulf chemo, radio and the anti-XYZ IO easily. The key is PdtSer-Targeting, Dr. Wolchok said it explicitly and hence the key is a threat for all that are invested or still purring revenue out of competing technologies for CAR-T+PS-Targeting for all solid cancers.

And then we didn't even mention Biomarkers, also PdtSer-IP based, that now that Sunrise identified them and lead to patents, will allow to speed up clinical trial tremendously. That on its own, due to time to market, is big.

And Beta-bodies, the a full human version of Bavituximab, with new patents and related protection, all in the portfolio of PPHM, unencumbered.
...
...